Corporate News – Market Update
Spero Therapeutics (SPRO) Declines Amidst Sector‑Wide Volatility
Spero Therapeutics (SPRO) closed the trading session on Friday, 23 August 2026, 4.1 % lower than the previous day’s close, at USD 1.13. The drop, recorded at 05:42 AM Central Europe time, reflects a broader trend of downward pressure on the biopharmaceutical sector.
With a total outstanding supply of 58.2 million shares, SPRO’s market capitalization stands at USD 71.1 million. Over the past 24 hours, the stock has been traded for approximately USD 310.9 k, a modest volume compared with its average daily turnover.
The company’s price trajectory has been notably bearish in the recent month, declining 13.97 % since the end of July. The 200‑day simple moving average (SMA) sits at USD 2.03, indicating a significant deviation below the medium‑term trend. In a broader historical context, SPRO’s all‑time high reached USD 3.08 on 27 May 2026, while the 52‑week low of USD 1.08 was recorded on 24 July 2026.
Comparative Performance of Peer Stocks
In the same 24‑hour window, the following peer companies exhibited varied performance:
| Ticker | 24‑Hour Movement | Current Price | Market Cap (USD mn) |
|---|---|---|---|
| LGL (The) | +2.56 % | 6.65 | 82.8 |
| MGLD (Marygold /The) | 0 % | 1.97 | 84.1 |
| CRBP (Corbus Holdi) | –3.05 % | 4.13 | 82.9 |
| SOTK (Sono‑tek) | –1.7 % | 5.09 | 83.2 |
| AAWH (Ascend Wellness) | –2.47 % | 0.42 | 83.3 |
Sono‑tek’s price‑to‑earnings ratio currently stands at 44.5, indicating a valuation that may be considered high relative to industry peers.
Company Profile
Spero Therapeutics, Inc. is a biopharmaceutical firm headquartered in Cambridge, Massachusetts, specializing in the discovery, development, and commercialization of novel therapeutics for multidrug‑resistant (MDR) bacterial infections. The company also operates a technology platform designed to broaden the efficacy and spectrum of existing antibiotics. SPRO went public on the Nasdaq exchange on 2 November 2017 and has since focused on expanding its pipeline of antimicrobial agents through both in‑house research and strategic collaborations.
